MiMedx Group

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MiMedx Group reports robust Q4 performance and eyes growth opportunities

MiMedx Group's Q4 2022 earnings call highlighted strong performance, strategic focus on growth objectives, and addressing challenges in reimbursement and regulatory landscape. The company's emphasis on technology, personnel, and growth opportunities positions it for continued success.

MiMedx Group reports robust Q1 performance and eyes international growth

MiMedx Group's Q1 2023 performance reflects a balanced focus on profitability and revenue growth, driven by new product launches and strategic initiatives.
Despite challenges such as product launch delays and market dynamics, the company remains optimistic about growth opportunities in Japan and beyond.
With a strong emphasis on efficiency, innovation, and market expansion, MiMedx Group is positioned for continued growth and success in the evolving healthcare landscape.

MiMedx Group excels in Q2, eyes growth amid challenges

MiMedx Group's Q2 2023 performance reflects strong financial results, operational efficiency, and a strategic shift towards wound and surgical markets.
While facing challenges related to supply chain disruptions and regulatory compliance, the company is well-positioned to capitalize on growth opportunities and drive innovation.
Investors can be optimistic about MiMedx Group's financial outlook, legal standing, and commitment to market expansion through product development and strategic partnerships.

MiMedx Group reports robust Q3 earnings, eyes Japanese market growth

MiMedx Group's Q3 performance reflects strong financial results, strategic product launches, and growth in key markets despite challenges.
The company's focus on operational efficiency, expansion in the Japanese market, and product portfolio diversification position it well for future success.
While facing challenges from Medicare LCD changes and potential cannibalization, MiMedx remains optimistic about growth opportunities and aims for continued momentum.

MiMedx Group excels in Q4, poised for sustained growth

MiMedx Group's Q4 performance exceeded expectations with revenue growth and improved margins.
The company's strategic focus on growth drivers and financial discipline sets a strong foundation for 2024.
While facing challenges in certain areas, MiMedx is well-positioned to capitalize on opportunities for expansion.
Overall, MiMedx's financial health and growth prospects indicate a positive outlook for the future.

MiMedx Group reports robust Q1 earnings amidst strategic growth plans

MiMedx Group (MDXG) had a strong start in Q1 2024, showcasing financial strength and strategic focus on growth.
The company faces challenges from potential market disruptions and cost pressures but remains optimistic about opportunities.
Key initiatives include product innovation, market expansion, and navigating reimbursement landscape changes.

MiMedx Group reports solid Q2 earnings, navigates reimbursement challenges

MiMedx Group's Q2 performance reflects steady growth, strong financial health, and a strategic focus on innovation and customer relationships.
While facing challenges in reimbursement dynamics and regulatory uncertainties, the company remains resilient and poised for growth opportunities in the market.
With a solid product portfolio and emphasis on operational efficiency, MiMedx Group is well-positioned to navigate challenges and capitalize on future market prospects.

MiMedx Group reports solid Q3 growth amid reimbursement challenges

MiMedx Group's Q3 performance reflects resilience and growth amidst challenges, with a focus on innovation and customer-centric strategies for future success.
The company's financial stability, positive market reception of HELIOGEN, and increasing platform adoption position it well for capitalizing on opportunities ahead.
While facing challenges in reimbursement dynamics and operational efficiency, MiMedx Group remains optimistic about future corrections and growth prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MiMedx (MDXG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

MiMedx (MDXG) is on the Move, Here's Why the Trend Could be Sustainable

If you are looking for stocks that are well positioned to maintain their recent uptrend, MiMedx (MDXG) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why

The mean of analysts' price targets for MiMedx (MDXG) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in MiMedx (MDXG)? Wall Street Analysts Think 37.12%

MiMedx (MDXG) Is a Great Choice for 'Trend' Investors, Here's Why

Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs' Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update on the Local Coverage Determinations (“LCDs”) regarding “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.

MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs

The consensus price target hints at a 77.9% upside potential for MiMedx (MDXG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can MiMedx (MDXG) Climb 77.92% to Reach the Level Wall Street Analysts Expect?

MiMedx Group, Inc. (NASDAQ:MDXG ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Group Ross Osborn - Cantor Fitzgerald Brad Bowers - Mizuho Securities Carl Byrnes - Northland Capital Markets Operator Good afternoon, and thank you for standing by. Welcome to the MiMedx Third Quarter 2024 Operating and Financial Results Conference Call.

MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript

MiMedx (MDXG) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.05 per share a year ago.

MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates

Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05 , Respectively Third Quarter Adjusted EBITDA was $18 Million, or 22% of Net Sales Raises 2024 Net Sales Growth Expectations to the High Single-Digits Management to Host Conference Call Today, October 30, 2024, at 4:30 PM ET

MIMEDX Announces Third Quarter 2024 Operating and Financial Results

MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2024 after the market close on Wednesday, October 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30

MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today highlighted the publication of a feature article on placental allografts for patients with hard-to-heal, acute and chronic wounds, which was published in today's New York Times: “Her Face Was Unrecognizable After an Explosion.

MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue

Company to Sponsor Lunch Symposium and Hands-On Skills Lab Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research   MARIETTA, Ga., Oct. 01, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place October 2-5 in Las Vegas, NV.

MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall

10 Former MiMedx Employees In Non-Compete Suit Fight Back Against MiMedx Schemes to "Bilk Medicare" and "Incentivize Fraud" in Counterclaims Filed by Mintz Attorneys MARIETTA, Ga. , Sept. 11, 2024 /PRNewswire/ -- 10 former employees of MiMedx Group, Inc. (NASDAQ: MDXG) have now filed counterclaims against the placental biologics company in response to a non-compete lawsuit filed by MiMedx earlier this year.

EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS"

Ex-MiMedx Employee Jake Heikkinen Files Counterclaims Alleging Schemes 'To Bilk Medicare' and 'Incentivize and Pressure Healthcare Providers' per Mintz Attorneys MARIETTA, Ga. , Sept. 4, 2024 /PRNewswire/ -- The third of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the company.

THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'

Ex-MiMedx Employee Caralyn Gargan Files Counterclaims for "Predatory Sales Practices" and "Incentivized Fraud" per Mintz Attorneys MARIETTA, Ga. , Aug. 26, 2024 /PRNewswire/ -- One of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the placental biologics company.

DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT

MiMedx Group, Inc. (NASDAQ:MDXG ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Chase Knickerbocker - Craig-Hallum Capital Group Brooks O'Neil - Lake Street Capital Markets Anthony Petrone - Mizuho Group Carl Byrnes - Northland Capital Markets Operator Greetings and welcome to the MiMedx Second Quarter 2024 Operating and Financial Results Conference Call. At this time, all participants are in a listen-only mode.

MiMedx Group, Inc. (MDXG) Q2 2024 Earnings Call Transcript

Limited market release marks first xenograft addition to Company's portfolio of leading Wound and Surgical products Limited market release marks first xenograft addition to Company's portfolio of leading Wound and Surgical products

MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix

Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12 , Respectively Second Quarter Adjusted EBITDA was $20 Million, or 23% of Net Sales Management to Host Conference Call Today, July 31, 2024 , at 4:30 PM ET MARIETTA, Ga., July 31, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2024.

MIMEDX Announces Second Quarter 2024 Operating and Financial Results

Study adds to the Company's growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process

MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports

Harmony Biosciences Holdings

Incyte

MEI Pharma

Procaps Group SA

SCYNEXIS

United Therapeutics

Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.

7 Undervalued Biotech Stocks to Buy for Big-Time Returns

MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020.

MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer

MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:

MIMEDX to Participate in Upcoming Investor Conferences

MiMedx Group, Inc. (NASDAQ:MDXG ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Matt Notarianni - Head of Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Brooks O'Neil - Lake Street Capital Markets Anthony Petrone - Mizuho Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright John Vandermosten - Zacks Operator Good afternoon and thank you for standing by.

MiMedx Group, Inc. (MDXG) Q1 2024 Earnings Call Transcript

Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call Today, April 30, 2024 , at 4:30 PM ET MARIETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the first quarter 2024.

MIMEDX Announces First Quarter 2024 Operating and Financial Results

MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

News for MiMedx Group Stock (MDXG)